Brief: Ose Immunotherapeutics Announces The Continuation Of Its Phase 2 Trial In Ulcerative Colitis

Ose Immunotherapeutics SA

13/12/2021 17:11

Dec 13 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS IS PLEASED TO ANNOUNCE CONTINUATION
OF
ITS PHASE 2 TRIAL TESTING ANTI-IL-7 RECEPTOR ANTAGONIST
OSE-127/S95011 IN ULCERATIVE COLITIS AFTER INTERIM FUTILITY
ANALYSIS
    * BASED ON RECOMMENDATION OF TRIAL'S IDMC, OSE
IMMUNOTHERAPEUTICS
WILL PROCEED WITH STUDY
    * ANNOUNCES TRIAL'S INDEPENDENT DATA MONITORING COMMITTEE
(IDMC)
COMPLETED PLANNED SAFETY AND EFFICACY ASSESSMENT FOR FUTILITY OF
ONGOING PHASE 2 CLINICAL TRIAL IN ULCERATIVE COLITIS PATIENTS
AND RECOMMENDED CONTINUATION OF STUDY

Source text for Eikon:  ID:nGNX9v9rgb 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))